Concert Pharmaceuticals Inc (CNCE)
Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 inhibitor that Co. discovered through the application of its DCE Platform® (deuterated chemical entity platform). Co. is evaluating CTP-543 in a Phase 3 clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. In addition to its wholly-owned development programs, Co. has entered into collaborative arrangements with companies to develop deuterium-modified versions of their marketed products.
|
March 29, 2024 1:17 AM Eastern
Buy (3.00 out of 4)
100th percentile
|
|